At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Fulvestrant +1 moredrug
Likely dose
Anastrazole 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Fulvestrant and Anastrazole for Invasive Breast Cancer. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Breast Cancer
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedJun 2009
Primary CompletionApr 2015
Study CompletionMar 2023
TodayJul 2026
First PostedJun 16, 2009
Enrollment StartMay 1, 2009
Primary CompletionApr 1, 2015
Study CompletionMar 20, 2023
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 17.0 years ago
Interventions
Fulvestrantdrug
Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
Anastrazoledrug
Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles